Figure 3.
CD81KO cells have diminished CD19 surface expression and disruption of BTK signaling. (A) Flow cytometry plot overlays showing the Nalm6 surface expression of CD19 in CD81KO compared with WT. Isotype control antibody plot is included for reference. Representative plot of 3 independent trials is shown. (B) Western blot analysis of phosphorylated BTK in CD81KO Nalm6 cells compared WT after 4 hours of serum starvation. (C) Western blot analysis of p53 and Bax in untreated and Ara-C-treated CD81KO Nalm6 cells compared with untreated and Ara-C-treated WT cells. (D) Western blot analysis of p53 and Bax in WT Nalm6 cells in monoculture treated with fenebrutinib (25 nM) or LFM-A13 (10 μM) for 16 hours. (B-D) Representative blots of 3 independent trials are shown. Numbers below the blot indicate average fold change of protein normalized to GAPDH (loading control) with respect to control (assigned value = 1.00) from 3 independent experiments.

CD81KO cells have diminished CD19 surface expression and disruption of BTK signaling. (A) Flow cytometry plot overlays showing the Nalm6 surface expression of CD19 in CD81KO compared with WT. Isotype control antibody plot is included for reference. Representative plot of 3 independent trials is shown. (B) Western blot analysis of phosphorylated BTK in CD81KO Nalm6 cells compared WT after 4 hours of serum starvation. (C) Western blot analysis of p53 and Bax in untreated and Ara-C-treated CD81KO Nalm6 cells compared with untreated and Ara-C-treated WT cells. (D) Western blot analysis of p53 and Bax in WT Nalm6 cells in monoculture treated with fenebrutinib (25 nM) or LFM-A13 (10 μM) for 16 hours. (B-D) Representative blots of 3 independent trials are shown. Numbers below the blot indicate average fold change of protein normalized to GAPDH (loading control) with respect to control (assigned value = 1.00) from 3 independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal